| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/12/2008 | US20080138390 Increased permeation of the active agent through the skin, an improved capability of extracting the active agent and enhancer from the transdermal systems, enhanced structural integrity, good chemical stability, reduced phase separation, and decreased cold flow |
| 06/12/2008 | US20080138389 Contains a solvent-free matrix layer containing (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol; increased solubility |
| 06/12/2008 | US20080138388 Contains a basic drug (donepezil) having an octanol/water partition coefficient in the free state of 3 or above, a pressure-sensitive adhesive base and a methacrylic acid and methyl methacrylate |
| 06/12/2008 | US20080138386 Crosslinkable Saccharide-Siloxane Compositions, and Networks, Coatings and Articles Formed Therefrom |
| 06/12/2008 | US20080138385 2-mercaptopyridine-N-oxide sodium, carbendazim (methyl 1H-2-benzimidazole carbamate), or thiabendazole (2-(4-thiazolyl)-1H-benzimidazole); halogen-free; synergistic effect |
| 06/12/2008 | US20080138384 Oral hair growth stimulants comprising orthosiphon |
| 06/12/2008 | US20080138383 Compositions and methods for treating seizures |
| 06/12/2008 | US20080138382 Biocompatible intraocular implants include a steroid and a polymer; biodegradable; eye implantable drug delivery systems; few or no negative side effects |
| 06/12/2008 | US20080138379 Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy |
| 06/12/2008 | US20080138377 Vasodilator Eluting Luminal Stent Devices With A Specific Polyphosphazene Coating and Methods for Their Manufacture and Use |
| 06/12/2008 | US20080138376 Polidocanol; a sclerosant liquid for treatment of varicose veins |
| 06/12/2008 | US20080138369 Of a water soluble hydroxyalkyl cellulose polymer, corn starch, a flavorant that is released in a burst and decorative, cosmetic and therapeutic agents; improved whitening, desensitization, breath freshening |
| 06/12/2008 | US20080138351 Liposome treatment of viral infections |
| 06/12/2008 | US20080138322 Pretreating with lipophilic substituted saccharide |
| 06/12/2008 | US20080138296 Alcohol-free; oil in water nanoemulsion comprising nano oil globules; anionic, cationic or nonionic surfactant stabilizer; water; liquefied or compressed gas propellant; homogeneity, aging resistance; breakable foam in pressurized container; improved bubble size; skin disorders; anticarcinogenic agents |
| 06/12/2008 | US20080138295 Administering cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide; side effect reduction from chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy; anticarcinogenic and antimetastasis agents; autoimmune diseases |
| 06/12/2008 | US20080138294 Drug delivery of a nicotine formulation in a single pulmonary dose; free of tobacco; multiple containers; aerosols, inhalants; may also administer an antidepressant or anxiolytic agent; smoking termination |
| 06/12/2008 | US20080138293 Alcohol-free carrier comprising water, hydrophobic solvent, foam adjuvant of (hydroxyl-substituted and/or unsaturated) fatty alcohols and/or fatty acids; surfactant, and water gelling agent; sensitivity, non-drying; liquefied or compressed gas propellant in container |
| 06/12/2008 | US20080135812 Cu(Ac)2 and/or In(Ac)3 and selenourea is dissolved in water and sonicated for about 1 hour or more under an atmosphere of inert gas, to form CuSe or In2Se3 or CuInSe2 nanoparticles ; oxide-free ink; solar cells |
| 06/12/2008 | US20080135811 Solution-based fabrication of photovoltaic cell |
| 06/12/2008 | US20080135099 Solution-based fabrication of photovoltaic cell |
| 06/12/2008 | CA2823981A1 Film-coated preparation having improved stability |
| 06/12/2008 | CA2671975A1 Film-coated preparation having improved stability |
| 06/12/2008 | CA2671636A1 Pharmaceutical composition for external application and adhesive skin patch |
| 06/12/2008 | CA2671571A1 High protein concentration formulations containing mannitol |
| 06/12/2008 | CA2671461A1 Vesicles of self-assembling block copolymers and methods for making and using the same |
| 06/12/2008 | CA2671447A1 Amphiphilic entity nanoparticles |
| 06/12/2008 | CA2671420A1 Method of forming a tablet |
| 06/12/2008 | CA2670887A1 Modified release ibuprofen solid oral dosage form |
| 06/12/2008 | CA2670886A1 Oral transmucosal nicotine dosage form |
| 06/12/2008 | CA2670749A1 Drug delivery |
| 06/12/2008 | CA2670746A1 Intraocular drug delivery systems |
| 06/12/2008 | CA2668947A1 Liquid anti-rabies antibody formulations |
| 06/12/2008 | CA2667209A1 Improved linkers for anchoring targeting ligands |
| 06/12/2008 | CA2658521A1 Enhanced immediate release formulations of topiramate |
| 06/11/2008 | EP1930436A1 Vector for delivering target substance into nucleus or cell |
| 06/11/2008 | EP1930337A1 Water-soluble metal alcoholate derivative, process for production of the derivative, and solid gelatinous agent for external application comprising the derivative |
| 06/11/2008 | EP1930030A1 Pulse preparation having improved disintegration properties in vivo |
| 06/11/2008 | EP1930029A1 Particle for medical use and process for producing the same |
| 06/11/2008 | EP1930028A1 Non-invasive drug delivery system targeting posterior eye tissue using solid composition |
| 06/11/2008 | EP1930027A2 A composition of sodium channel blocking compound |
| 06/11/2008 | EP1930024A2 G-CSF solution formulations having long-term stability |
| 06/11/2008 | EP1930012A1 Cellooligosaccharide-containing composition |
| 06/11/2008 | EP1930006A1 Method for production of quinolone-containing lyophilized preparation |
| 06/11/2008 | EP1930005A1 Stabilized formulation of selective ligands of retinoic acid gamma-receptors |
| 06/11/2008 | EP1930002A1 Use of hydroxybenzoic acid ester and analogues for the manufacture of a mendicament for the prevention and treatment of virus infection |
| 06/11/2008 | EP1929998A2 Controlled release solid dispersions of carvedilol |
| 06/11/2008 | EP1929997A1 Oxcarbazepine formulations |
| 06/11/2008 | EP1929996A2 Ophthalmic emulsions containing an immunosuppressive agent |
| 06/11/2008 | EP1929995A1 Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
| 06/11/2008 | EP1928863A2 Pharmaceutical dosage forms and compositions comprising lecoztan |
| 06/11/2008 | EP1928597A1 Method for the attachment of nanoparticles to substrate particles |
| 06/11/2008 | EP1928594A2 Method for production of single- and multi-layer microcapsules |
| 06/11/2008 | EP1928493A2 Stabilization of clostridium botulinum neurotoxin complex |
| 06/11/2008 | EP1928485A2 Stable pharmaceutical compositions including motilin-like pepetides |
| 06/11/2008 | EP1928476A1 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| 06/11/2008 | EP1928459A2 Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 06/11/2008 | EP1928441A2 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation |
| 06/11/2008 | EP1928439A2 Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear |
| 06/11/2008 | EP1928436A2 Application system for a plaster containing an active ingredient and a controlled-release agent for said active ingredient |
| 06/11/2008 | EP1928435A2 Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| 06/11/2008 | EP1928434A2 Self-assembling nanoparticles for the treatment of vascular diseases |
| 06/11/2008 | EP1928433A2 Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
| 06/11/2008 | EP1928432A2 Method for the encapsulation and controlled-release of poorly water-soluble (hydrophobic) liquid and solid active ingredients |
| 06/11/2008 | EP1928431A2 Controlled release pharmaceutical composition containing carvedilol |
| 06/11/2008 | EP1928430A1 Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| 06/11/2008 | EP1928429A2 Effervescent oral care compositions and methods of use |
| 06/11/2008 | EP1928428A2 A pharmaceutical formulation containing olanzapine |
| 06/11/2008 | EP1928427A1 Novel dosage formulation |
| 06/11/2008 | EP1928426A2 Method for stabilising pharmaceutical administration forms that contain micro-organisms |
| 06/11/2008 | EP1928425A1 Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
| 06/11/2008 | EP1928424A2 Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof |
| 06/11/2008 | EP1928423A2 Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| 06/11/2008 | EP1928422A2 Improvements in the stabilisation of biological materials |
| 06/11/2008 | EP1928421A2 Formulations containing glimepiride and/or its salts |
| 06/11/2008 | EP1928420A1 Treatment of inflammation and vascular abnormalities of the eye |
| 06/11/2008 | EP1928419A1 Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant |
| 06/11/2008 | EP1928418A1 Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant |
| 06/11/2008 | EP1928417A2 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 06/11/2008 | EP1928416A2 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 06/11/2008 | EP1928415A2 Topical delivery with a carrier fluid |
| 06/11/2008 | EP1928414A2 Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions |
| 06/11/2008 | EP1928413A1 Hfsh aqueous formulation |
| 06/11/2008 | EP1928412A2 Aqueous anaesthetic compositions comprising propofol |
| 06/11/2008 | EP1928411A2 Use of octenidine dihydrochloride in semisolid preparations |
| 06/11/2008 | EP1928410A2 Antibiotic formulations, unit doses, kits, and methods |
| 06/11/2008 | EP1928409A2 Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| 06/11/2008 | EP1928408A1 Orodispersible tablets of bitter active principles |
| 06/11/2008 | EP1928407A1 Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma |
| 06/11/2008 | EP1928406A2 Pharmaceutical compositions with melting point depressant agents and method of making same |
| 06/11/2008 | EP1928405A1 Pharmaceutical compositions for the treatment of inner ear disorders |
| 06/11/2008 | EP1928313A1 Self-assembled biodegradable polymersomes |
| 06/11/2008 | EP1928235A2 Composition and method for use in cartilage affecting conditions |
| 06/11/2008 | EP1758612B1 Composition comprising intercalated functional-active organic compounds |
| 06/11/2008 | EP1740186B1 Biodegradable intraocular implants containing prostamides |
| 06/11/2008 | EP1734965A4 New compositions and methods for maintaining eyelid hygiene |
| 06/11/2008 | EP1729778B1 Pharmaceutical preparation containing drospirenone for application to the skin |
| 06/11/2008 | EP1715944B1 Mixture comprising a detergent and a co-detergent |
| 06/11/2008 | EP1689374B1 Self-supporting films for pharmaceutical and food use |
| 06/11/2008 | EP1517709B1 Transdermal drug delivery system |